News Headlines Article

Alzheimer’s drug bapineuzumab fails late-stage trial, research dropped
San Francisco Business Times

Bapineuzumab, one of the drug-development industry’s promising Alzheimer’s disease treatments, failed in a late-stage trial, Pfizer Inc. and its partner said Monday, dealing another blow to the Alzheimer’s community of patients, doctors and caregivers. The news came on the same day as researchers from the Gladstone Institutes in San Francisco said they discovered an already-approved anti-epilepsy drug that may eventually be used by Alzheimer’s patients.